Current Progress in the Science of Novel Adjuvant Nano-Vaccine-Induced Protective Immune Responses

Mansab Ali Saleemi,Yan Zhang,Guoquan Zhang

DOI: https://doi.org/10.3390/pathogens13060441

IF: 3.7

2024-05-24

Pathogens

Abstract:Vaccinations are vital as they protect us from various illness-causing agents. Despite all the advancements in vaccine-related research, developing improved and safer vaccines against devastating infectious diseases including Ebola, tuberculosis and acquired immune deficiency syndrome (AIDS) remains a significant challenge. In addition, some of the current human vaccines can cause adverse reactions in some individuals, which limits their use for massive vaccination program. Therefore, it is necessary to design optimal vaccine candidates that can elicit appropriate immune responses but do not induce side effects. Subunit vaccines are relatively safe for the vaccination of humans, but they are unable to trigger an optimal protective immune response without an adjuvant. Although different types of adjuvants have been used for the formulation of vaccines to fight pathogens that have high antigenic diversity, due to the toxicity and safety issues associated with human-specific adjuvants, there are only a few adjuvants that have been approved for the formulation of human vaccines. Recently, nanoparticles (NPs) have gain specific attention and are commonly used as adjuvants for vaccine development as well as for drug delivery due to their excellent immune modulation properties. This review will focus on the current state of adjuvants in vaccine development, the mechanisms of human-compatible adjuvants and future research directions. We hope this review will provide valuable information to discovery novel adjuvants and drug delivery systems for developing novel vaccines and treatments.

microbiology

What problem does this paper attempt to address?

This paper aims to solve some key problems in vaccine development, especially the development of effective vaccines for those difficult - to - treat infectious diseases such as Ebola, tuberculosis and AIDS. Although much progress has been made in vaccine research, developing more effective and safer vaccines remains a major challenge. Specifically, this paper focuses on the following aspects:

1. **Limitations of existing vaccines**: Some current human vaccines may cause adverse reactions in individuals, which limits their use in large - scale vaccination programs. Therefore, it is necessary to design optimal vaccine candidates that can trigger an appropriate immune response without side effects.

2. **Challenges of subunit vaccines**: Although subunit vaccines are relatively safe, they usually cannot trigger the best protective immune response without adjuvants. However, due to the toxicity and safety issues of human - specific adjuvants, only a few adjuvants have been approved for the formulation of human vaccines.

3. **Nanoparticles as new adjuvants**: In recent years, nanoparticles have received special attention because of their excellent immunomodulatory properties and are often used in vaccine development and drug delivery. The paper explores the current status, mechanism and future research directions of nanoparticles in vaccine development.

4. **Improving vaccine efficacy and safety**: By designing new adjuvant systems, it aims to improve the efficacy and delivery of immunomodulatory substances, so as to improve the safety and effectiveness of vaccines while reducing side effects.

In conclusion, this paper attempts to explore how to use these technologies to overcome the limitations of existing vaccines and develop new, safer and more effective vaccines by reviewing the application of nanoparticles in vaccine development.